In light of the withdrawal of its annual objectives, bioMérieux, a world leader in the field of in vitro diagnostics, today announced preliminary quarterly information about its business activity ending June 30, 2020.
- Organic growth of 15.7% at constant exchange rates and scope of consolidation over the first half of 2020:
- €1,476 million in sales
- Up 15.8% as reported
- Sustained positive momentum of molecular biology product lines
- As expected, adverse impact of the global health crisis on microbiology, immunoassay and industrial applications product lines